Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
J Immunol. 2012 Dec 1;189(11):5147-54. doi: 10.4049/jimmunol.1200274. Epub 2012 Oct 24.
Administration of nonmyeloablative chemotherapeutic agents or total body irradiation (TBI) prior to adoptive transfer of tumor-specific T cells may reduce or eliminate immunosuppressive populations such as T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSC). Little is known about these populations during immune reconstitution. This study was designed to understand the reconstitution rate and function of these populations post TBI in melanoma tumor-bearing mice. Reconstitution rate and suppressive activity of CD4(+)CD25(+)Foxp3(+) Tregs and CD11b(+)Gr1(+) MDSC following TBI-induced lymphopenia was measured in B16 melanoma tumor-bearing mice. To ablate the rapid reconstitution of suppressive populations, we treated mice with docetaxel, a known chemotherapeutic agent that targets MDSC, in combination with adoptive T cell transfer and dendritic cell immunotherapy. Both Treg and MDSC populations exhibited rapid reconstitution after TBI-induced lymphopenia. Although reconstituted Tregs were just as suppressive as Tregs from untreated mice, MDSC demonstrated enhanced suppressive activity of CD8(+) T cell proliferation compared with endogenous MDSC from tumor-bearing mice. TBI-induced lymphopenia followed by docetaxel treatment improved the efficacy of adoptive T cell transfer and dendritic cell immunotherapy in melanoma-bearing mice, inducing a significant reduction in tumor growth and enhancing survival. Tumor regression correlated with increased CTL activity and persistence of adoptively transferred T cells. Overall, these findings suggest that TBI-induced MDSC are highly immunosuppressive and blocking their rapid reconstitution may improve the efficacy of vaccination strategies and adoptive immunotherapy.
在过继输注肿瘤特异性 T 细胞之前,给予非清髓性化疗药物或全身照射(TBI)可能会减少或消除免疫抑制群体,如调节性 T 细胞(Tregs)和髓源抑制细胞(MDSC)。关于这些群体在免疫重建期间的情况知之甚少。本研究旨在了解 TBI 后在黑色素瘤荷瘤小鼠中这些群体的重建率和功能。在 B16 黑色素瘤荷瘤小鼠中,测量 TBI 诱导的淋巴细胞减少后 CD4(+)CD25(+)Foxp3(+)Tregs 和 CD11b(+)Gr1(+)MDSC 的重建率和抑制活性。为了消除抑制性群体的快速重建,我们用多西紫杉醇(一种针对 MDSC 的已知化疗药物)联合过继性 T 细胞转移和树突状细胞免疫疗法治疗小鼠。TBI 诱导的淋巴细胞减少后,Treg 和 MDSC 群体均迅速重建。尽管重建的 Tregs 与未处理小鼠的 Tregs 一样具有抑制作用,但与荷瘤小鼠内源性 MDSC 相比,MDSC 对 CD8(+)T 细胞增殖的抑制活性增强。TBI 诱导的淋巴细胞减少后用多西紫杉醇治疗可提高黑色素瘤荷瘤小鼠过继性 T 细胞转移和树突状细胞免疫疗法的疗效,显著减少肿瘤生长并提高存活率。肿瘤消退与 CTL 活性的增加和过继转移 T 细胞的持续存在相关。总的来说,这些发现表明 TBI 诱导的 MDSC 具有高度的免疫抑制作用,阻断其快速重建可能会提高疫苗策略和过继免疫疗法的疗效。
Chin Med J (Engl). 2012-3
Clin Cancer Res. 2008-5-15
Onco Targets Ther. 2025-8-29
Front Oncol. 2023-8-10
Cancer Res Commun. 2023-3
Int J Mol Sci. 2022-9-18
Cancer Immunol Immunother. 2022-9
Nat Cancer. 2022-1
Nat Rev Immunol. 2012-3-22
Nat Rev Drug Discov. 2012-2-3